Oppenheimer & Co.

Oppenheimer is maintaining its Outperform rating and is raising its price target from $27 to $35 on Questcor Pharmaceuticals (NASDAQ: QCOR) as the company continues to exceed expectations. In the report, Oppenheimer states, “On 7/26, QCOR reported 2Q11 adj. EPS of $0.23, above our $0.17 estimate...

Oppenheimer & Co. is out with a research report on Mastercard (NYSE: MA) and is reiterating its Outperform rating and is raising its price target to $345 from $315. In a note to clients, Oppenheimer & Co. writes, "We reiterate our Outperform ratings on Visa and MasterCard, moderately raise...

Oppenheimer & Co. is out with a research report on Visa (NYSE: V) and is raising its price target to $110 from $100, and it is reiterating its Outperform rating. In a note to clients, Oppenheimer & Co. writes, "We reiterate our Outperform ratings on Visa and MasterCard, moderately raise...

Oppenheimer & Co. is out with a research report on Taomee Holdings Ltd (NASDAQ: TAOM) and is initiating coverage with a Perform rating and a $15 price target on shares. In a note to clients, Oppenheimer & Co. writes, "We are initiating coverage on Taomee Holdings Limited (TAOM) with a...

Oppenheimer & Co. is out with a research report on VMware (NYSE: VMW) after it reported earnings. It has a Perform rating on shares. In a note to clients, Oppenheimer & Co. writes, "VMW reported stellar 2Q results, with upside on all metrics driven by strong market demand. During the...

Oppenheimer & Co. is initiating coverage on Clayton Williams Energy, Inc. (NASDAQ: CWEI) with a Buy rating and a $100 price target. In a note to clients, Oppenheimer & Co. writes, "We are initiating coverage of Clayton Williams Energy, Inc. (CWEI) with a Buy rating and $100 price target on...

Oppenheimer & Co. is out with a research report on Citigroup (NYSE: C) after it reported earnings on Friday. The price target is being lowered to $53 from $55, but it still has an Overweight rating on shares. In a note to clients, Oppenheimer & Co. writes, "While it was not a sterling...

Oppenheimer & Co. is out with a research report on Clorox (NYSE: CLX) and is downgrading the name to Perform from Outperform. In a note to clients, Oppenheimer & Co. writes, "We are downgrading CLX to Perform from Outperform and suggest investors use Friday's strength and all-time high...

Oppenheimer & Co. is raising its price target on shares of Seattle Genetics (NASDAQ: SGEN) to $24 from $21, and it is keeping its Outperform rating on shares. In a note to clients, Oppenheimer & Co. writes, "On 7/14, an FDA Advisory Committee (AdCom) voted unanimously (10-0) in favor of...

Oppenheimer & Co. is out with a research report on Tiffany's (NYSE: TIF) and is raising its price target to $100 from $80. It has an Outperform rating on shares. In a note to clients, Oppenheimer & Co. writes, "We have for some time recommended Tiffany as one of the most attractive...

Oppenheimer & Co. is out with a research report on Microsoft (NASDAQ: MSFT), as the company provided a glimpse at Windows Server 8. It has an Outperform rating on shares. In the note, Oppenheimer & Co. writes, "On Tuesday, MSFT provided its partners with an early preview of Windows Server...

Oppenheimer & Co. is reiterating its Outperform rating and $36 price target on shares of Elizabeth Arden (NASDAQ: RDEN). In a note to clients, Oppenheimer & Co. writes, "While shares of RDEN have been somewhat range-bound throughout much of this year, our bull case remains very much intact...

Oppenheimer & Co. is out with a research report on Gilead (NASDAQ: GILD), as the company released ph.III results for GILD's QUAD pill. It has an Outperform rating and a $45 price target. In a note to clients, Oppenheimer writes, "With ph.III results for GILD's QUAD pill vs. Truvada/Reyataz (...

Oppenheimer & Co. is initiating coverage on shares of HollyFrontier Corp. (NYSE: HFC) with an Outperform rating and a $90 price target. In a note to clients, Oppenheimer & Co. writes, "We are initiating coverage of HFC with an Outperform rating and a $90 price target. Created from the...

Oppenheimer & Co. is upgrading shares of Microsemi Corp. (NASDAQ: MSCC) to Outperform and putting a $28 price target on shares. In a note to clients, Oppenheimer & Co. writes, "We are upgrading MSCC to Outperform from Perform and establishing a $28 price target. In selecting the best semi...